Prostate cancer metastatic

• 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending
  2025-520861-29-00 5 "Prostate cancer at risk of developing metastatic lesions"
• Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending
  2025-520868-17-00 5 "Cancer on the prostatic bed"
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 "Metastatic Castrate Sensitive Prostate Cancer - mCSPC"
• A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2025-521327-67-00 4 2026-04-13 "Metastatic Castration-Resistant Prostate Cancer"
• First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting
  2025-521886-28-00 1 2026-02-19 "Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metas"
• A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer Recruiting
  2023-504063-17-00 1 2024-03-08 "Advanced Prostate Cancer"
• A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into, … Recruiting
  2022-502623-22-00 1 2023-09-18 "Metastatic castration-resistant prostate cancer"
• (Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting
  2024-520026-11-00 7 2026-03-19 "Metastatic Prostate Cancer"
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 "METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER"
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 "Metastatic castrate resistant prostate cancer - mCRPC"
• Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting
  2025-521051-23-00 4 2025-08-06 "metastatic castration-resistant prostate cancer"
• A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (c … Recruiting
  2022-503132-14-00 3 2025-06-30 "Metastatic Prostate Cancer"
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 4 2025-04-11 "Metastatic prostate cancer"
• Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer. Recruiting
  2024-515527-11-00 1 2025-03-20 "Prostate cancer"
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 "METASTATIC CASTRATION RESISTANT PROSTATE CANCER"
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting
  2023-504013-68-00 1 2024-09-06 "Advanced or Metastatic Prostate Cancer"
• Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s … Recruiting
  2024-515049-41-00 4 2024-07-12 "metastatic prostate cancer"
• Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting
  2023-510536-37-00 4 2024-07-05 "Prostate Cancer"
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 "Oligometastatic prostate cancer (OMPC)"
• A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Cas … Recruiting
  2023-505898-32-00 9 2024-02-28 "Metastasic Castration-Resistant Prostate Cancer (mCRPC)"
• Measuring Oncological Value of Exercise and Statin (MOVES) Recruiting
  2024-515109-24-00 5 2023-03-31 "Metastatic breast, ovarian, prostate and kidney cancer"
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 "Adenocarcinoma of the prostate"
• Phase I study of 225Ac-PSMA I&T in prostate cancer Recruiting
  2024-513729-22-01 2 2022-02-01 "metastatic prostate cancer"
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 5 2019-01-08 "Prostate Cancer"

Showing 1–24 of 47 trials